Komal Jhaveri

home / authors / komal-jhaveri

Articles

16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation

16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation

Matthew P. Goetz, MD;Seth A. Wander;Thomas Bachelot;Gerald Batist;Javier Cortés, MD;Massimo Cristofanilli, MD;Giuseppe Curigliano;Alexandre de Nonneville;Einav Nili Gal-Yam;Komal Jhaveri;Cynthia X. Ma, MD, PhD;Heather A. Parsons, MD, MPH;Hope S. Rugo, MD;Sarah L. Sammons;Daniel G. Stover;Chris Twelves, MD, FRCP;Aditya Bardia, MD, MPH;Paul V. Plourde;David J. Portman;Senthil Damodaran
August 12th 2024
30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial

30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri;Seock-Ah Im;Senia Pernas;Michelino De Laurentiis;Shusen Wang;Noelia Martínez Jañez;Giuliano Borges;David W. Cescon;Masaya Hattori;Yen-Shen Lu;Erika P. Hamilton, MD;Qingyuan Zhang;Junji Tsurutani;Kevin Kalinsky, MD, MS;Lu Xu;Neelima Denduluri;Binghe Xu;Barbara Pistilli
July 20th 2024
48 Sacituzumab Govitecan (SG) Efficacy in Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2– Negative (HR+/HER2–) Metastatic Breast Cancer (mBC) by HER2 Immunohistochemistry (IHC) Status in the Phase 3 TROPiCS-02 Study

48 Sacituzumab Govitecan (SG) Efficacy in Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2– Negative (HR+/HER2–) Metastatic Breast Cancer (mBC) by HER2 Immunohistochemistry (IHC) Status in the Phase 3 TROPiCS-02 Study

Sara M. Tolaney, MD, MPH;Peter Schmid, MD;Javier Cortes;Frederik Marmé;Hope S. Rugo, MD;Mafalda Oliveira;Delphine Loirat;Komal Jhaveri;Oh Kyu Yoon;Monica Motwani;Hao Wang;Rosemary Delaney;Aditya Bardia, MD, MPH
April 27th 2023
54 Quality of Life With Ribociclib Plus Aromatase Inhibitor vs Abemaciclib Plus Aromatase Inhibitor as First-line Treatment of HR+/HER2− Advanced Breast Cancer, Assessed via Matching- Adjusted Indirect Comparison (MAIC)

54 Quality of Life With Ribociclib Plus Aromatase Inhibitor vs Abemaciclib Plus Aromatase Inhibitor as First-line Treatment of HR+/HER2− Advanced Breast Cancer, Assessed via Matching- Adjusted Indirect Comparison (MAIC)

Hope S. Rugo, MD;Joyce O'Shaughnessy, MD;Komal Jhaveri;Sara M. Tolaney, MD, MPH;Fatima Cardoso;Aditya Bardia, MD, MPH;Purnima Pathak;Sina Haftchenary;Peter A. Fasching
April 26th 2023

Latest Updated Articles

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Metastatic Renal Cell Carcinoma With Sarcomatoid Features
Published: April 15th 2022 | Updated: October 23rd 2024
Metastatic Renal Cell Carcinoma With Sarcomatoid Features
A 78-Year-Old Woman With Nonpruritic Periorbital Purpura Around Her Eyelids
Published: August 13th 2011 | Updated: October 23rd 2024
A 78-Year-Old Woman With Nonpruritic Periorbital Purpura Around Her Eyelids
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
Published: August 26th 2011 | Updated: October 23rd 2024
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes